RegeneRx partner G-treeBNT gears up for Phase III dry eye trials with RGN-259
The trial of RGN-259 (a Thymosin Beta 4-based preservative-free eye drop) is based on data secured from a 72-patient, double-masked, placebo-controlled trial sponsored by RegeneRx and conducted by